Germain, D. P., Blattmann, P., Cybulla, M., Frey, A., Gudmundsson, K., Jovanovic, A., … Barisoni, L. (2026). Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study. In Molecular Genetics and Metabolism (Vol. 147, pp. 109423–109423). Elsevier BV. https://doi.org/10.1016/j.ymgme.2025.109423

Germain, Dominique P., Peter Blattmann, Markus Cybulla, Aline Frey, Kolbeinn Gudmundsson, Ana Jovanovic, Michael Meinel, et al. “Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study.” In Molecular Genetics and Metabolism, 147:109423–109423. Elsevier BV, 2026. https://doi.org/10.1016/j.ymgme.2025.109423.

Germain DP, Blattmann P, Cybulla M, Frey A, Gudmundsson K, Jovanovic A, et al. Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study. In: Molecular Genetics and Metabolism. Elsevier BV; 2026. p. 109423–109423.

Germain, Dominique P., et al. “Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study.” Molecular Genetics and Metabolism, vol. 147, no. 2, Elsevier BV, 2026, pp. 109423–109423. Crossref, doi:10.1016/j.ymgme.2025.109423.

Germain DP, Blattmann P, Cybulla M, Frey A, Gudmundsson K, Jovanovic A, Meinel M, Moreno V, Nordbeck P, Thomas DB, Barisoni L. Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study. Molecular Genetics and Metabolism. Elsevier BV; 2026. p. 109423–109423.